Rise in Drug-Resistant Fungal Infections Across the U.S.
This year, there’s been a concerning uptick in cases of a potentially lethal drug-resistant fungus. Provisional data from the CDC shows that **several thousand** instances of Candida auris (C. auris) have emerged across 27 states.
As of late July, there were **3,437 clinical cases** reported in the United States. A notable number of these cases, about 873, are from California—making up about a quarter of the total. Other states with significant counts include Texas with 433 cases, Tennessee at 283, Ohio with 279, and a few others like Georgia and Illinois following closely.
The remaining states each have under 100 reported cases, but the overall numbers still raise red flags.
Candida auris is a type of yeast that poses serious infection risks, especially in environments like hospitals and nursing homes. It has the ability to survive on various surfaces for extended periods, making it worryingly contagious through contact with contaminated objects—think bedrails and doorknobs. The CDC notes that even individuals carrying the fungus without visible symptoms can spread it.
A clinical case, as defined by the CDC, indicates the detection of C. auris in samples collected during normal medical evaluations. However, it’s important to remember that not all these cases represent active infections; some might simply indicate colonization.
The health implications of this fungus can vary widely. Some people might only experience colonization with no symptoms, while others could face severe invasive infections, including bloodstream complications. Those most at risk tend to have serious health conditions, particularly patients reliant on various medical devices like ventilators and catheters.
Dr. Marc Siegel, a clinical professor at NYU Langone, describes C. auris as “an emerging problem of great concern.” He highlights its resistance to multiple antifungal treatments and its prevalence in healthcare settings. Symptoms, he mentions, can be quite generic—fever, chills, and general discomfort—making it easy to confuse with other infections.
Mortality rates associated with invasive C. auris infections range from **30% to 72%**, though many affected individuals are already gravely ill, complicating the task of pinpointing how often the fungus directly leads to death.
One of the most troubling aspects is the resistance this fungus shows against common treatments. The CDC classifies C. auris as an “urgent antimicrobial-resistance threat.” Over 90% of samples analyzed in the U.S. exhibit resistance to fluconazole, a standard antifungal medication. Echinocandins are currently the primary treatment option, yet some strains demonstrate resistance to all major antifungal classes.
Dr. Siegel notes that research is actively underway to develop new treatments. He emphasizes that this situation is part of a broader issue with emerging antibiotic resistance both in the U.S. and globally, while also suggesting that improved sterilization and disinfection efforts in healthcare facilities could significantly help manage the spread.
